Variant position: 1162 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1382 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human EIADGMAYLNAKKFVHRDLA ARNCMVAHDFTVKIGDFGMTR
Mouse EIADGMAYLNAKKFVHRDLA ARNCMVAHDFTVKIGDFGMTR
Rat EIADGMAYLNAKKFVHRDLA ARNCMVAHDFTVKIGDFGMTR
Xenopus laevis EISDGMAYLNAKKFVHRDLA ARNCMVADDYAVKIGDFGMTR
Caenorhabditis elegans QICDGMAYLESLKFCHRDLA ARNCMINRDETVKIGDFGMAR
Drosophila EIADGMAYLAAKKFVHRDLA ARNCMVADDLTVKIGDFGMTR
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Substitution of glutamic acid for alanine 1135 in the putative 'catalytic loop' of the tyrosine kinase domain of the human insulin receptor. A mutation that impairs proteolytic processing into subunits and inhibits receptor tyrosine kinase activity.
Cama A.; de la Luz Sierra M.; Quon M.J.; Ottini L.; Gorden P.; Taylor S.I.;
J. Biol. Chem. 268:8060-8069(1993)
Cited for: CHARACTERIZATION OF VARIANT IRAN TYPE A GLU-1162;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.